Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.

Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment

Open access
Fan, Yuxin, Xue, Han, Li, Zhimin, Huo, Mingge, Gao, Hongxia, Guan, Xingang·2024·Frontiers in Pharmacology

Abstract

Cancer cells have adapted to rapid tumor growth and evade immune attack by reprogramming their metabolic pathways. Glutamine is an important nitrogen resource for synthesizing amino acids and nucleotides and an important carbon source in the tricarboxylic acid (TCA) cycle and lipid biosynthesis pathway. In this review, we summarize the significant role of glutamine metabolism in tumor development and highlight the vulnerabilities of targeting glutamine metabolism for effective therapy. In particular, we review the reported drugs targeting glutaminase and glutamine uptake for efficient cancer treatment. Moreover, we discuss the current clinical test about targeting glutamine metabolism and the prospective direction of drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2024.1345522

Cites

264 of 264 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Glutamine metabolism pathways in cancer cells. Glutamine is transported to the cytoplasm by glutamine transporters on the cell membrane (SLC1A5, SLC38A1, and SLC6A14) and then to the mitochondria via SLC1A5 variants. In the mitochondrial matrix, glutamine is converted to glutamate by GLS. The resulting glutamate is converted into α-KG by GLUD1, GOT2, and GPT2 to enter the TCA cycle and further participate in the biosynthesis of amino acids, nucleotides, and lipids. Malic acid produced by the TCA cycle crosses the mitochondrial membrane into the cytoplasm and is oxidized by malate dehydrogenase to produce OAA. The OAA can be converted to aspartic acid and transported out of the cytoplasm, where malic acid and further OAA are formed. The OAA in the cytoplasm is converted to pyruvate by malidase and is used to produce NADPH, which is involved in maintaining redox homeostasis in tumor cells. Glutamate produced by glutamine in mitochondria can escape to the cytoplasm and be transported by SLC7A11 on the cell membrane to exchange cystine, further forming cysteine and participating in de novo synthesis of GSH. The medium purple box show the glutamine metabolic inhibitors at each step. GLS, glutaminase; α-KG, α-ketoglutarate; GLUD1, glutamate dehydrogenase 1; GOT, glutamate oxaloacetate transaminase; GPT, glutamate pyruvate transaminase; TCA, tricarboxylic acid; OAA, oxaloacetic acid; NADPH, nicotinamide adenine dinucleotide phosphate; GSSG, oxidized glutathione; GSH, oxidized glutathione.
FIGURE 1 Glutamine metabolism pathways in cancer cells. Glutamine is transported to the cytoplasm by glutamine transporters on the cell membrane (SLC1A5, SLC38A1, and SLC6A14) and then to the mitochondria via SLC1A5 variants. In the mitochondrial matrix, glutamine is converted to glutamate by GLS. The resulting glutamate is converted into α-KG by GLUD1, GOT2, and GPT2 to enter the TCA cycle and further participate in the biosynthesis of amino acids, nucleotides, and lipids. Malic acid produced by the TCA cycle crosses the mitochondrial membrane into the cytoplasm and is oxidized by malate dehydrogenase to produce OAA. The OAA can be converted to aspartic acid and transported out of the cytoplasm, where malic acid and further OAA are formed. The OAA in the cytoplasm is converted to pyruvate by malidase and is used to produce NADPH, which is involved in maintaining redox homeostasis in tumor cells. Glutamate produced by glutamine in mitochondria can escape to the cytoplasm and be transported by SLC7A11 on the cell membrane to exchange cystine, further forming cysteine and participating in de novo synthesis of GSH. The medium purple box show the glutamine metabolic inhibitors at each step. GLS, glutaminase; α-KG, α-ketoglutarate; GLUD1, glutamate dehydrogenase 1; GOT, glutamate oxaloacetate transaminase; GPT, glutamate pyruvate transaminase; TCA, tricarboxylic acid; OAA, oxaloacetic acid; NADPH, nicotinamide adenine dinucleotide phosphate; GSSG, oxidized glutathione; GSH, oxidized glutathione.CC BY · PubMed Central
FIGURE 2 Chemical structure of inhibitors targeting glutaminase.
FIGURE 2 Chemical structure of inhibitors targeting glutaminase.CC BY · PubMed Central
FIGURE 3 Chemical structure of inhibitors targeting glutamine uptake and transformation.
FIGURE 3 Chemical structure of inhibitors targeting glutamine uptake and transformation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 263 references

Research works printed but not linked: 1

  1. Mickle, 2022, VGLL4 and glutamine deprivation suppress YAP1/TEAD signaling to attenuate the SCC cancer phenotype

Cited by

See all 45

Metadata

Authors
Fan, Y., Xue, H., Li, Z., Huo, M., Gao, H., & Guan, X.
Affiliations
  • Beihua University (CN)
  • Taizhou University (CN)
Corresponding author
  • Gao, Hongxia
  • Guan, Xingang
Venue
Frontiers in Pharmacology
Published
2024-03-06
Volume
15
Pages
1345522-1345522
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4392517467
Cited by
40
References
263
Citations by year
2026: 15 · 2025: 22 · 2024: 3
FWCI
1.95
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China
  • Beihua University
  • Science and Technology Plan Project of Taizhou (22gya03)
  • Natural Science Foundation of Zhejiang Province (LY23C100001)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
glutamine metabolism, cancer metabolism, glutaminase inhibitors, tumor metabolic reprogramming, TCA cycle, lipogenesis, cancer therapy, drug development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment. https://app.cochat.ai/papers/10.3389/fphar.2024.1345522
The paper
Fan, Y., Xue, H., Li, Z., Huo, M., Gao, H., & Guan, X. (2024). Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2024.1345522

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.